{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:03:46Z","timestamp":1792451026631,"version":"4.5.0"},"reference-count":30,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.36662","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T18:04:16Z","timestamp":1638381856000},"page":"e2136662","source":"Crossref","is-referenced-by-count":42,"title":["Association of Fluoroquinolone Prescribing Rates With Black Box Warnings from the US Food and Drug Administration"],"prefix":"10.1001","volume":"4","author":[{"given":"Ashwini","family":"Sankar","sequence":"first","affiliation":[{"name":"Carlson School of Management, Department of Finance, University of Minnesota, Minneapolis"},{"name":"Department of Economics, Macalester College, St Paul, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristi M.","family":"Swanson","sequence":"additional","affiliation":[{"name":"Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiani","family":"Zhou","sequence":"additional","affiliation":[{"name":"School of Public Health, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupam Bapu","family":"Jena","sequence":"additional","affiliation":[{"name":"Department of Health Care Policy, Harvard Medical School, Harvard University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Ross","sequence":"additional","affiliation":[{"name":"Yale University, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilay D.","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Health Care Policy and Research, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinar","family":"Karaca-Mandic","sequence":"additional","affiliation":[{"name":"Carlson School of Management, Department of Finance, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,12,1]]},"reference":[{"issue":"9","key":"zoi211037r1","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/pds.v25.9","article-title":"Off-label use of oral fluoroquinolone antibiotics in outpatient settings in the United States, 2006 to 2012.","volume":"25","author":"Almalki","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"zoi211037r2","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1186\/s12879-016-2091-0","article-title":"Regional variation in antibiotic prescribing among Medicare Part D enrollees, 2013.","volume":"16","author":"Arizpe","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"15","key":"zoi211037r5","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.jacc.2021.02.047","article-title":"Effects of fluoroquinolones on outcomes of patients with aortic dissection or aneurysm.","volume":"77","author":"Chen","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"zoi211037r8","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1001\/jamainternmed.2016.5651","article-title":"Estimating national trends in inpatient antibiotic use among US hospitals from 2006 to 2012.","volume":"176","author":"Baggs","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"12","key":"zoi211037r9","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1177\/1060028019865224","article-title":"Evaluation of FDA boxed warning on prescribing patterns of fluoroquinolones for uncomplicated urinary tract infections.","volume":"53","author":"Cowart","year":"2019","journal-title":"Ann Pharmacother"},{"issue":"6","key":"zoi211037r10","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1002\/pds.v29.6","article-title":"Outpatient fluoroquinolone prescribing patterns before and after US FDA boxed warning.","volume":"29","author":"Bratsman","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"zoi211037r11","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1017\/ice.2019.247","article-title":"Impact of FDA black box warning on fluoroquinolone and alternative antibiotic use in southeastern US hospitals.","volume":"40","author":"Yarrington","year":"2019","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"6","key":"zoi211037r12","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1001\/jamainternmed.2021.1154","article-title":"Association of US Food and Drug Administration removal of indications for use of oral quinolones with prescribing trends.","volume":"181","author":"Tran","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"8","key":"zoi211037r13","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1097\/00005650-199208000-00004","article-title":"The protracted demise of medical technology. The case of intermittent positive pressure breathing.","volume":"30","author":"Duffy","year":"1992","journal-title":"Med Care"},{"issue":"1","key":"zoi211037r14","first-page":"41","article-title":"Uptake and utilization of practice guidelines in hospitals in the United States: the case of routine episiotomy.","volume":"43","author":"Kozhimannil","year":"2017","journal-title":"Jt Comm J Qual Patient Saf"},{"key":"zoi211037r15","doi-asserted-by":"crossref","DOI":"10.1111\/1475-6773.13630","article-title":"Physician variation in the de-adoption of ineffective statin and fibrate therapy.","author":"Everhart","year":"2021","journal-title":"Health Serv Res"},{"issue":"3","key":"zoi211037r16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s10754-020-09282-2","article-title":"Patient and provider-level factors associated with changes in utilization of treatments in response to evidence on ineffectiveness or harm.","volume":"20","author":"Smith","year":"2020","journal-title":"Int J Health Econ Manag"},{"issue":"255","key":"zoi211037r17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12916-015-0488-z","article-title":"Towards understanding the de-adoption of low-value clinical practices: a scoping review.","volume":"13","author":"Niven","year":"2015","journal-title":"BMC Med"},{"issue":"5","key":"zoi211037r18","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jamainternmed.2015.0157","article-title":"Effect of published scientific evidence on glycemic control in adult intensive care units.","volume":"175","author":"Niven","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"3","key":"zoi211037r19","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-024159","article-title":"Barriers and facilitators to adopting high value practices and de-adopting low value practices in Canadian intensive care units: a multimethod study.","volume":"9","author":"Sauro","year":"2019","journal-title":"BMJ Open"},{"issue":"7","key":"zoi211037r20","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1097\/MLR.0000000000000735","article-title":"Identifying increased risk of readmission and in-hospital mortality using hospital administrative data: the AHRQ Elixhauser Comorbidity Index.","volume":"55","author":"Moore","year":"2017","journal-title":"Med Care"},{"issue":"6","key":"zoi211037r21","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/j.acap.2013.08.002","article-title":"Use of interrupted time series analysis in evaluating health care quality improvements.","volume":"13","author":"Penfold","year":"2013","journal-title":"Acad Pediatr"},{"issue":"4","key":"zoi211037r22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1046\/j.1365-2710.2002.00430.x","article-title":"Segmented regression analysis of interrupted time series studies in medication use research.","volume":"27","author":"Wagner","year":"2002","journal-title":"J Clin Pharm Ther"},{"issue":"1 Pt 1","key":"zoi211037r23","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1475-6773.2011.01314.x","article-title":"Interaction terms in nonlinear models.","volume":"47","author":"Karaca-Mandic","year":"2012","journal-title":"Health Serv Res"},{"issue":"2","key":"zoi211037r24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s41669-016-0007-y","article-title":"Utilization, spending, and price trends for quinolones in the US Medicaid programs: 25 years\u2019 experience 1991-2015.","volume":"1","author":"Almalki","year":"2017","journal-title":"Pharmacoecon Open"},{"issue":"2","key":"zoi211037r25","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3390\/antibiotics8020084","article-title":"Qualitative analysis of primary care provider prescribing decisions for urinary tract infections.","volume":"8","author":"Grigoryan","year":"2019","journal-title":"Antibiotics (Basel)"},{"key":"zoi211037r26","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jcrc.2015.12.007","article-title":"Adoption and de-adoption of drotrecogin alfa for severe sepsis in the United States.","volume":"32","author":"Kahn","year":"2016","journal-title":"J Crit Care"},{"issue":"9","key":"zoi211037r27","first-page":"1308","article-title":"US outpatient antibiotic prescribing variation according to geography, patient population, and provider specialty in 2011.","volume":"60","author":"Hicks","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"5","key":"zoi211037r28","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1128\/AAC.02897-15","article-title":"Antibiotic resistance among urinary isolates from female outpatients in the United States in 2003 and 2012.","volume":"60","author":"Sanchez","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"zoi211037r29","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/976273","article-title":"Global fluoroquinolone resistance epidemiology and implictions for clinical use.","volume":"2012","author":"Dalhoff","year":"2012","journal-title":"Interdiscip Perspect Infect Dis"},{"key":"zoi211037r3","unstructured":"US Food and Drug Administration. FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients: FDA Drug Safety Communication. December 21, 2018. Accessed April 10, 2020. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics"},{"key":"zoi211037r4","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: FDA requires label changes to warn of risk for possibly permanent nerve damage from antibacterial fluoroquinolone drugs taken by mouth or by injection. August 15, 2013. Accessed April 10, 2020. http:\/\/wayback.archive-it.org\/7993\/20170112031629\/http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm365050.htm"},{"key":"zoi211037r6","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. March 8, 2018. Accessed April 10, 2020. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-updates-warnings-oral-and-injectable-fluoroquinolone-antibiotics"},{"key":"zoi211037r7","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. May 12, 2016. Accessed April 10, 2020. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-advises-restricting-fluoroquinolone-antibiotic-use-certain"},{"key":"zoi211037r30","unstructured":"The Joint Commission. R3 Report Issue 23: antimicrobial stewardship in ambulatory health care. Accessed August 11, 2020. https:\/\/www.jointcommission.org\/r3_report_23_antimicrobial_stewardship_in_ambulatory_health_care\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2786698\/sankar_2021_oi_211037_1637599176.13838.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T18:04:28Z","timestamp":1638381868000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2786698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,1]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.36662","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,1]]}}}